Incidence of Melanoma in Catalonia, Spain, Is Rapidly Increasing in the Elderly Population. A Multicentric Cohort Study
- PMID: 33113930
- PMCID: PMC7690683
- DOI: 10.3390/jcm9113396
Incidence of Melanoma in Catalonia, Spain, Is Rapidly Increasing in the Elderly Population. A Multicentric Cohort Study
Abstract
The incidence of melanoma has been increasing worldwide during recent decades. The objective of the study was to analyse the trends in incidence for in situ and invasive melanoma in the Spanish region of Catalonia during the period of 2008-2017. We designed a cross-sectional study with an age-period-cohort analysis of melanoma patient data from the Network of Melanoma Centres in Catalonia. Our database covered a population of over seven million and included a total of 8626 patients with incident melanoma. The main outcome measures were crude and age-standardised incidence rates to the European 2013 standard population. Joinpoint regression models were used to evaluate the population trends. We observed an increase in the age-standardised incidence rate (per 100,000 population) of all melanoma subtypes from 11.56 in 2008 to 13.78 in 2017 with an average annual percent change (AAPC) of 3.5%. This incidence increase was seen exclusively in the older population. Moreover, the stratified analysis showed a statistically significant increase in the age-standardised incidence rate for invasive (AAPC 2.1%) and in situ melanoma (AAPC 6.5%). In conclusion, the incidence of melanoma has continued to increase in the elderly population over recent decades, with a rapidly increasing trend of in situ melanomas and the lentigo maligna subtype.
Keywords: Spain; epidemiology; incidence; melanoma; population-based study; skin cancer.
Conflict of interest statement
The authors have no conflict of interest to declare. The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of data, nor in the preparation, review, or approval of the manuscript.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7690683/bin/jcm-09-03396-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7690683/bin/jcm-09-03396-g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7690683/bin/jcm-09-03396-g003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7690683/bin/jcm-09-03396-g004.gif)
Similar articles
-
Increasing incidence of lentigo maligna and lentigo maligna melanoma in Catalonia.Int J Dermatol. 2019 May;58(5):577-581. doi: 10.1111/ijd.14334. Epub 2018 Dec 13. Int J Dermatol. 2019. PMID: 30548854
-
Lentigo maligna and lentigo maligna melanoma: contemporary issues in diagnosis and management.Melanoma Manag. 2015 May;2(2):171-178. doi: 10.2217/mmt.15.3. Epub 2015 May 18. Melanoma Manag. 2015. PMID: 30190846 Free PMC article. Review.
-
Trends in incidence of thick, thin and in situ melanoma in Europe.Eur J Cancer. 2018 Mar;92:108-118. doi: 10.1016/j.ejca.2017.12.024. Epub 2018 Jan 31. Eur J Cancer. 2018. PMID: 29395684
-
Italian cancer figures, report 2012: Cancer in children and adolescents.Epidemiol Prev. 2013 Jan-Feb;37(1 Suppl 1):1-225. Epidemiol Prev. 2013. PMID: 23585445 English, Italian.
-
Lentigo maligna melanoma--the review.Coll Antropol. 2010 Apr;34 Suppl 2:299-301. Coll Antropol. 2010. PMID: 21305747 Review.
Cited by
-
Spain's Rising Melanoma Threat: A Comprehensive 30-Year Analysis (1990-2019).Cancers (Basel). 2024 Mar 15;16(6):1167. doi: 10.3390/cancers16061167. Cancers (Basel). 2024. PMID: 38539502 Free PMC article.
-
Differences in the phospholipid profile of melanocytes and melanoma cells irradiated with UVA and treated with cannabigerol and cannabidiol.Sci Rep. 2023 Sep 26;13(1):16121. doi: 10.1038/s41598-023-43363-9. Sci Rep. 2023. PMID: 37752196 Free PMC article.
-
Spaghetti Technique Versus Wide Local Excision for Lentigo Maligna Affecting the Head and Neck Regions: Surgical Outcome and Descriptive Analysis of 79 Cases from a Single Practice Cohort.Dermatol Pract Concept. 2023 Jul 1;13(3):e2023193. doi: 10.5826/dpc.1303a193. Dermatol Pract Concept. 2023. PMID: 37557139 Free PMC article.
-
Skin cancer special issue in Skin Health and Disease.Skin Health Dis. 2023 Mar 10;3(2):e224. doi: 10.1002/ski2.224. eCollection 2023 Apr. Skin Health Dis. 2023. PMID: 37013119 Free PMC article. No abstract available.
-
Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma.Front Pharmacol. 2022 Nov 1;13:1039416. doi: 10.3389/fphar.2022.1039416. eCollection 2022. Front Pharmacol. 2022. PMID: 36386136 Free PMC article.
References
-
- Stratigos A.J., Forsea A.M., van der Leest R.J.T., de Vries E., Nagore E., Bulliard J.L., Trakatelli M., Paoli J., Peris K., Hercogova J., et al. Euromelanoma: A dermatology-led European campaign against nonmelanoma skin cancer and cutaneous melanoma. Past, present and future. Br. J. Dermatol. 2012;167:99–104. doi: 10.1111/j.1365-2133.2012.11092.x. - DOI - PubMed
Grants and funding
- 12/00840/Fondo de Investigaciones Sanitarias
- 15/00956/Fondo de Investigaciones Sanitarias
- 15/00716/Fondo de Investigaciones Sanitarias
- 00000/CIBER de Enfermedades Raras of the Instituto de Salud Carlos III
- 00000/Fondo Europeo de Desarrollo Regional (FEDER). Unión Europea. Una manera de hacer Europa
- 2014_SGR_603/AGAUR
- 2017_SGR_1134/AGAUR
- 201331-30/Fundació La Marató de TV3
- LSHC-CT-2006-018702/European Commission under the 6th Framework Programme
- 00000/CERCA Programme / Generalitat de Catalunya
- GCB15152978SOEN/Fundación Científica de la Asociación Española Contra el Cáncer
- PPRC-2017/19/the European Academy of Dermatology and Venereology (EADV)
- PI15/00711/ISCIII
- 00000/FEDER "Una manera de hacer Europa"
- CB16/12/00231/CIBERONC
- FMTV 201331-31/Fundació la Marató de TV3